Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Akebia Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AKBA
Nasdaq
2834
www.akebia.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Akebia Therapeutics, Inc.
Akebia Therapeutics (AKBA) Stock Fair Value Falls After Analysts Cut Targets Following Q3 Miss
- Nov 20th, 2026 6:12 am
Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
- Nov 17th, 2026 2:05 pm
Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
- Nov 16th, 2026 6:00 am
Akebia (AKBA) Q3 2026 Earnings Call Transcript
- Nov 6th, 2026 11:01 am
Akebia Therapeutics Inc (AKBA) (Q3 2026) Earnings Call Highlights: Vafseo Demand Outpaces ...
- Nov 6th, 2026 12:13 am
What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call
- Nov 5th, 2026 9:15 am
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
- Nov 5th, 2026 6:35 am
Akebia Therapeutics: Q3 Earnings Snapshot
- Nov 5th, 2026 5:24 am
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
- Nov 5th, 2026 5:10 am
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
- Nov 5th, 2026 5:00 am
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
- Oct 29th, 2026 6:00 am
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
- Oct 26th, 2026 7:20 am
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
- Oct 7th, 2026 6:00 am
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
- Oct 6th, 2026 6:00 am
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
- Sep 22nd, 2026 6:00 am
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
- Sep 15th, 2026 6:00 am
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
- Sep 14th, 2026 6:00 am
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sep 1st, 2026 2:05 pm
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
- Sep 1st, 2026 6:00 am
Scroll